David Hutton

In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment. Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.

An investigator at Anglia Ruskin University is leading work on an anti-cataract drug, which has had positive results in lab tests.

BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).

In research sponsored by Skye Bioscience Inc., investigators at the University of Mississippi have demonstrated stronger and longer-lasting reduction of intraocular pressure when a proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopol 940.

Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.

Dr David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.

The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a paediatric patient, with the company on track to complete dosing of the paediatric mid-dose cohort in the first half of 2022.

A team of investigators from Pohang University of Science and Technology has found that conjunctival goblet cell examination is important for the precise diagnosis and effective treatment of ocular surface diseases; however, CGC examination has not been possible until now due to lack of non-invasive devices.

Approval is based on year 1 data from the Phase III KESTREL and KITE trials investigating brolucizumab 6 mg versus aflibercept 2 mg in DMO patients.

The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.

New Zealand’s Ministry of Health has issued infringement notices to two ophthalmologists for seeing patients while unvaccinated.

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject in lowering IOP as a standalone treatment option without concomitant cataract surgery.

A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells—a class of neurons located in the retina that are critical for vision.

Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.

While investigators have found a link between dry eye and depression, the exact reasons behind the link are not immediately known.

Glaukos Corp’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilise and reshape the cornea.

Dr Lisa Nijm advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.

A team of investigators found that sigma 1 receptor, which is known to protect cells from stress, could turn out to be key to the function and survival of the neurons most impacted by glaucoma.

Russian bombs on Wednesday struck a hospital in Mariupol, Ukraine, damaging several buildings, including an ophthalmology department. Elsewhere, physicians are participating in relief efforts.

New World Medical notes that the intuitively designed Streamline features ClickPulse technology that targets the eye’s conventional outflow pathway.

The glaucoma toolbox is expanding to include laser, drug delivery systems and minimally invasive glaucoma surgery.

The companies note that the partnership will propel Ray Therapeutics’ lead optogenetics gene therapy to Phase 1-2 clinical trials.

Results from the study were presented by Dr Russell Tait, CEO of PolyActiva, at the Glaucoma 360 New Horizons Forum in San Francisco, California.

Alimera Sciences, Inc. announces statistically significant improvements in best corrected visual acuity, central subfield thickness and treatment burden for patients with diabetic macular oedema.

Dr Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

Dr Raymond Douglas discusses real-world adherence to teprotumumab as a treatment for thyroid eye disease.

Researchers know that parts of the retina are considered as biomarkers for Alzheimer disease, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.

Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.

At Angiogenesis, Dr David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

Dr Carl Regillo discusses the 100-week results of KESTREL and KITE, two pivotal Phase 3 studies for brolucizumab for the treatment of diabetic macular oedema.